| scholarly article | Q13442814 |
| P50 | author | Emily L Larkin | Q61089566 |
| Laura Kovanda | Q88595470 | ||
| P2093 | author name string | Jyotsna Chandra | |
| Pranab K Mukherjee | |||
| Mauricio Retuerto | |||
| Mahmoud Ghannoum | |||
| David Angulo | |||
| Katyna Borroto-Esoda | |||
| Nancy Isham | |||
| Christopher Hager | |||
| Lisa Long | |||
| Iman Salem | |||
| Steve Wring | |||
| P2860 | cites work | Invasive Infections with Multidrug-Resistant Yeast Candida auris, Colombia | Q28818814 |
| Comparative Pathogenicity of United Kingdom Isolates of the Emerging Pathogen Candida auris and Other Key Pathogenic Candida Species | Q28829671 | ||
| Paradoxical growth of Candida albicans in the presence of caspofungin is associated with multiple cell wall rearrangements and decreased virulence | Q30570494 | ||
| Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces | Q30799502 | ||
| Candida biofilms: antifungal resistance and emerging therapeutic options. | Q30829656 | ||
| Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins | Q31058690 | ||
| Nanoscale investigation of pathogenic microbial adhesion to a biomaterial | Q33207644 | ||
| Candida albicans Als3p is required for wild-type biofilm formation on silicone elastomer surfaces | Q33250648 | ||
| Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital | Q33401940 | ||
| In vitro growth and analysis of Candida biofilms | Q33404034 | ||
| Biofilm formation and genotyping of Candida haemulonii, Candida pseudohaemulonii, and a proposed new species (Candida auris) isolates from Korea. | Q33609053 | ||
| Potential role of phospholipases in virulence and fungal pathogenesis | Q33812431 | ||
| Candida Albicans: a molecular revolution built on lessons from budding yeast | Q34161985 | ||
| First three reported cases of nosocomial fungemia caused by Candida auris | Q34196357 | ||
| Fungal biofilms | Q34229591 | ||
| New clonal strain of Candida auris, Delhi, India | Q34372060 | ||
| Biofilm production by isolates of Candida species recovered from nonneutropenic patients: comparison of bloodstream isolates with isolates from other sources | Q34453558 | ||
| First hospital outbreak of the globally emerging Candida auris in a European hospital | Q34543358 | ||
| Oral mycobiome analysis of HIV-infected patients: identification of Pichia as an antagonist of opportunistic fungi | Q35120262 | ||
| Multidrug-Resistant Candida auris Misidentified as Candida haemulonii: Characterization by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry and DNA Sequencing and Its Antifungal Susceptibility Profile Variability by Vitek | Q35586995 | ||
| Biofilm formation by Candida species on the surface of catheter materials in vitro | Q35775012 | ||
| Candida albicans-epithelial interactions and pathogenicity mechanisms: scratching the surface. | Q36147122 | ||
| Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous forms of Candida albicans during infection | Q36370514 | ||
| Analysis of the Candida albicans Als2p and Als4p adhesins suggests the potential for compensatory function within the Als family | Q36973123 | ||
| Chemical screening identifies filastatin, a small molecule inhibitor of Candida albicans adhesion, morphogenesis, and pathogenesis. | Q37104113 | ||
| Interaction of Candida albicans with host cells: virulence factors, host defense, escape strategies, and the microbiota | Q38752373 | ||
| Pathogenesis of Candida albicans biofilm | Q38767464 | ||
| First report of Candida auris in America: Clinical and microbiological aspects of 18 episodes of candidemia | Q39092138 | ||
| Incidence, characteristics and outcome of ICU-acquired candidemia in India | Q39092143 | ||
| Multidrug-resistant endemic clonal strain of Candida auris in India. | Q39092162 | ||
| Itraconazole-resistant Candida auris with phospholipase, proteinase and hemolysin activity from a case of vulvovaginitis | Q39092224 | ||
| Role of Tec1 in the development, architecture, and integrity of sexual biofilms of Candida albicans | Q41629515 | ||
| Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates | Q41907600 | ||
| Changes in cell wall synthesis and ultrastructure during paradoxical growth effect of caspofungin on four different Candida species. | Q42111171 | ||
| Candida auris-associated candidemia, South Africa | Q42712931 | ||
| Candida auris candidemia in Kuwait, 2014. | Q42787996 | ||
| Use of the protease fluorescent detection kit to determine protease activity | Q42854706 | ||
| Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features | Q43521723 | ||
| Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species | Q44380989 | ||
| In vitro colonization of an experimental silicone by Candida albicans | Q44897968 | ||
| The UNITE database for molecular identification of fungi--recent updates and future perspectives | Q48065164 | ||
| Investigation of the First Seven Reported Cases of Candida auris, a Globally Emerging Invasive, Multidrug-Resistant Fungus-United States, May 2013-August 2016. | Q50985111 | ||
| Candida albicans binds to saliva proteins selectively adsorbed to silicone. | Q51129556 | ||
| Plate method for detection of phospholipase activity in Candida albicans | Q70222244 | ||
| Extracellular phospholipases as universal virulence factor in pathogenic fungi | Q74526178 | ||
| Additive antifungal activity of anidulafungin and human neutrophils against Candida parapsilosis biofilms | Q82787605 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phenotype | Q104053 |
| biofilm | Q467410 | ||
| Candida auris | Q26816853 | ||
| emerging pathogen | Q108429945 | ||
| P577 | publication date | 2017-04-24 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation | |
| P478 | volume | 61 |
| Q89080678 | A rare fungus on the rise: Candida auris |
| Q57457108 | Activity of anti-CR3-RP polyclonal antibody against biofilms formed by Candida auris, a multidrug-resistant emerging fungal pathogen |
| Q90618019 | Antifungal Resistance: Specific Focus on Multidrug Resistance in Candida auris and Secondary Azole Resistance in Aspergillus fumigatus |
| Q41632930 | Antifungal resistance: current trends and future strategies to combat |
| Q118163247 | Biological potential of bioactive metabolites derived from fungal endophytes associated with medicinal plants |
| Q50042600 | CD101, a Novel Echinocandin, Possesses Potent Antibiofilm Activity against Early and Mature Candida albicans Biofilms |
| Q92859506 | Candida auris Biofilm Colonization on Skin Niche Conditions |
| Q92859499 | Candida auris Forms High-Burden Biofilms in Skin Niche Conditions and on Porcine Skin |
| Q89510130 | Candida auris, an Agent of Hospital-Associated Outbreaks: Which Challenging Issues Do We Need to Have in Mind? |
| Q89944189 | Candida auris: A Decade of Understanding of an Enigmatic Pathogenic Yeast |
| Q33704302 | Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally |
| Q48220845 | Candida auris: A systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen |
| Q46255772 | Candida auris: An Emerging Fungal Pathogen |
| Q64068234 | Candida auris: An emerging pathogen "incognito"? |
| Q53690366 | Candida auris: Disinfectants and Implications for Infection Control. |
| Q95642098 | Candida auris: From Multidrug Resistance to Pan-Resistant Strains |
| Q49988058 | Candida auris: a Review of the Literature. |
| Q39092282 | Candida auris: a worrisome, globally emerging pathogen |
| Q50117670 | Candida-Epithelial Interactions |
| Q89278451 | Clinical Pharmacokinetics and Drug-Drug Interaction Potential for Coadministered SCY-078, an Oral Fungicidal Glucan Synthase Inhibitor, and Tacrolimus |
| Q92320618 | Combined Antifungal Resistance and Biofilm Tolerance: the Global Threat of Candida auris |
| Q60922206 | Conserved Role for Biofilm Matrix Polysaccharides in Drug Resistance |
| Q50128552 | Containment strategies to address the expanding threat of multidrug-resistant Candida auris |
| Q89578301 | Contributions of the Biofilm Matrix to Candida Pathogenesis |
| Q33823084 | Development of a CRISPR-Cas9 System for Efficient Genome Editing of Candida lusitaniae |
| Q38798805 | Drug development challenges and strategies to address emerging and resistant fungal pathogens |
| Q39375330 | Drugs currently under investigation for the treatment of invasive candidiasis |
| Q54957028 | Echinocandins for management of invasive candidiasis in patients with liver disease and liver transplantation. |
| Q92707855 | Efficacy of Delayed Therapy with Fosmanogepix (APX001) in a Murine Model of Candida auris Invasive Candidiasis |
| Q92082086 | Emerging Fungal Infections: New Patients, New Patterns, and New Pathogens |
| Q59137597 | Enfumafungin synthase represents a novel lineage of fungal triterpene cyclases |
| Q39092300 | Environmental Surfaces in Healthcare Facilities are a Potential Source for Transmission of Candida auris and Other Candida Species |
| Q58598193 | Epidemiology, clinical characteristics, resistance, and treatment of infections by |
| Q90683654 | Factors associated with the development of septic shock in patients with candidemia: a post hoc analysis from two prospective cohorts |
| Q90124888 | First Report of Candida auris Spondylodiscitis in Oman: A Rare Presentation |
| Q55547464 | First cases and risk factors of super yeast Candida auris infection or colonization from Shenyang, China. |
| Q55017741 | First reported case of multidrug-resistant Candida auris in Canada. |
| Q46257698 | Fluconazole Resistant Candida auris is Susceptible to Salivary Histatin 5 Killing and to Intrinsic Host Defenses |
| Q91868199 | Fungal Cell Wall: Emerging Antifungals and Drug Resistance |
| Q49679927 | Gaining Insights from Candida Biofilm Heterogeneity: One Size Does Not Fit All. |
| Q61807390 | Genetic Analysis of Implicates Hsp90 in Morphogenesis and Azole Tolerance and Cdr1 in Azole Resistance |
| Q57793431 | Hog1 Regulates Stress Tolerance and Virulence in the Emerging Fungal Pathogen Candida auris |
| Q89885707 | Hope on the Horizon: Novel Fungal Treatments in Development |
| Q92932769 | Improved efficacy of antifungal drugs in combination with monoterpene phenols against Candida auris |
| Q53789385 | In Vitro Activity of a Novel Glucan Synthase Inhibitor, SCY-078, against Clinical Isolates of Candida auris. |
| Q39092177 | In Vitro Interactions of Echinocandins with Triazoles Against Multidrug-Resistant Candida auris |
| Q47195606 | In vitro and in vivo Evaluation of the Antifungal Activity of APX001A/APX001 Against Candida auris |
| Q92039317 | In vitro antifungal activity of a novel topical triazole PC945 against emerging yeast Candida auris |
| Q90573021 | In vitro antifungal combination of flucytosine with amphotericin B, voriconazole, or micafungin against Candida auris shows no antagonism |
| Q89288908 | Invasive Candida auris infections in Kuwait hospitals: epidemiology, antifungal treatment and outcome |
| Q88628103 | Lack of Impact by SCY-078, a First-in-Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug-Drug Interactions |
| Q64120011 | Linking Cellular Morphogenesis with Antifungal Treatment and Susceptibility in Pathogens |
| Q64268336 | Metabolic Profiling of Candida auris, a Newly-Emerging Multi-Drug Resistant Candida Species, by GC-MS |
| Q92666321 | Multi-omics Signature of Candida auris, an Emerging and Multidrug-Resistant Pathogen |
| Q47734944 | New opportunities for managing acute and chronic lung infections |
| Q94464436 | Nine Things Genomics Can Tell Us About Candida auris |
| Q91739554 | Ospemifene displays broad-spectrum synergistic interactions with itraconazole through potent interference with fungal efflux activities |
| Q55334499 | Peptide-Like Nylon-3 Polymers with Activity against Phylogenetically Diverse, Intrinsically Drug-Resistant Pathogenic Fungi. |
| Q50065359 | Preclinical testing of a broad-spectrum antimicrobial endotracheal tube coated with an innate immune synthetic mimic |
| Q64074437 | Random Mutagenesis Applied to Reveal Factors Involved in Oxidative Tolerance and Biofilm Formation in Foodborne |
| Q39092215 | Rapid and Accurate Molecular Identification of the Emerging Multidrug-Resistant Pathogen Candida auris |
| Q46258749 | Rare fungal infectious agents: a lurking enemy. |
| Q46257806 | Relative Resistance of the Emerging Fungal Pathogen Candida auris and Other Candida Species to Killing by Ultraviolet Light |
| Q58772251 | Responding to the emergence of antifungal drug resistance: perspectives from the bench and the bedside |
| Q64134876 | The Fungal Cyp51-Specific Inhibitor VT-1598 Demonstrates and Activity against Candida auris |
| Q92416972 | The NDV-3A vaccine protects mice from multidrug resistant Candida auris infection |
| Q98665147 | Transcriptional and functional insights into the host immune response against the emerging fungal pathogen Candida auris |
| Q55689919 | Transcriptome Assembly and Profiling of Candida auris Reveals Novel Insights into Biofilm-Mediated Resistance. |
| Q58772447 | Treatment of Invasive Candidiasis: A Narrative Review |
| Q60958254 | What Have We Learned About Its Mechanisms of Pathogenicity? |
Search more.